Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by houbahopon Dec 23, 2022 5:14am
154 Views
Post# 35188885

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:7500000

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:7500000"I'll be the first to criticize the company's communication strategy, but that's to highlight the opportunities for improvement,"

Thera's BoD had years to take decisions to improve its communication.
This problem is not new to this company. They have a proven track record of 20 years+.
I know it, you know it.

If the Directors did not take the opportunity to improve their communication toward their shareholders, it is because they don't see it has a problem. In Theratechnologie business culture, fiduciary duties towards their shareholders is irrelevant.

In conclusion, after years of making their shareholders irrelevant, it is now rational to "tear the company down". Normal reaction toward a very toxic company.

What is NOT normal, is to have the same posters, still trying to flip science even if they are now major bagholders. I agree it is now too late to sell shares at these low price, but it is counterintuitive to sell a prospect of a bounce in the share price in the near future.
<< Previous
Bullboard Posts
Next >>